PE20010216A1 - Procedimiento para preparar derivados de 10,11-metanobenzosuberano - Google Patents

Procedimiento para preparar derivados de 10,11-metanobenzosuberano

Info

Publication number
PE20010216A1
PE20010216A1 PE2000000541A PE0005412000A PE20010216A1 PE 20010216 A1 PE20010216 A1 PE 20010216A1 PE 2000000541 A PE2000000541 A PE 2000000541A PE 0005412000 A PE0005412000 A PE 0005412000A PE 20010216 A1 PE20010216 A1 PE 20010216A1
Authority
PE
Peru
Prior art keywords
compound
reacting
formula
methanobenzosuberan
derivatives
Prior art date
Application number
PE2000000541A
Other languages
English (en)
Inventor
Thomas Michael Wilson
Julie Kay Bush
Bret Eugene Huff
Susan Marie Reutzel-Edens
Tourneau Michael Edward Le
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010216A1 publication Critical patent/PE20010216A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR DERIVADOS DE 10,11-METANOBENZOSUBERANO DE FORMULA I, DONDE: A ES -CH2-CH2-, -CH2-CHRa-CH2-, -CH2-CHRa-CH2-CH2; Ra ES OH; R1 Y R2 SON H, F, Cl, Br; R3 ES HETEROARILO, FENILO OPCIONALMENTE SUSTITUIDO CON F, Cl, Br, CF3, CN, NO2, OCHF2 QUE COMPRENDE: a) REACCIONAR UN COMPUESTO (4) CON UNA FUENTE DE NUCLEOFILOS PARA FORMAR UN COMPUESTO (5); b) REACCIONAR UN COMPUESTO (5) CON PIRAZINA PARA FORMAR UN COMPUESTO (6); c) REDUCIR EL COMPUESTO (6) PARA FORMAR UN COMPUESTO (8); d) REACCIONAR UN COMPUESTO (8) CON i) UN COMPUESTO EPOXIDICO DE FORMULA (9) ii)UN COMPUESTO HALO DE FORMULA X1-(CH2)m-O-R3, X1 ES HALO, m ES 2-4; e)FORMAR UNA SAL DEL COMPUESTO (9) o (10). TAMBIEN SE REFIERE A LA PREPARACION DE COMPUESTOS INTERMEDIOS. UN COMPUESTO PREFERIDO ES TRICLORHIDRATO DE (2R)-ANTI-5-{3-[4-(10,11-DIFLUOROMETANODIBENZOSUBER-5-IL)PIPERAZIN-1-IL]-2-HIDROXIPROPOXI}QUINOLINA HIDRATO CRISTALINO, HIDRATO I, QUE SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X. LOS COMPUESTOS PUEDEN SER UTILES PARA EL TRATAMIENTO DEL CANCER
PE2000000541A 1999-06-03 2000-06-01 Procedimiento para preparar derivados de 10,11-metanobenzosuberano PE20010216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13728399P 1999-06-03 1999-06-03

Publications (1)

Publication Number Publication Date
PE20010216A1 true PE20010216A1 (es) 2001-02-27

Family

ID=22476642

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000541A PE20010216A1 (es) 1999-06-03 2000-06-01 Procedimiento para preparar derivados de 10,11-metanobenzosuberano

Country Status (18)

Country Link
US (1) US6521755B1 (es)
EP (1) EP1189887A2 (es)
JP (1) JP2003501421A (es)
KR (1) KR100692351B1 (es)
AR (1) AR037068A1 (es)
AU (1) AU5123300A (es)
BR (1) BR0011559A (es)
CA (1) CA2378735A1 (es)
CO (1) CO5170530A1 (es)
EG (1) EG24072A (es)
HU (1) HUP0203421A3 (es)
IL (2) IL146810A0 (es)
MX (1) MXPA01012296A (es)
MY (1) MY123517A (es)
PE (1) PE20010216A1 (es)
SV (1) SV2002000088A (es)
TW (1) TWI267511B (es)
WO (1) WO2000075121A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60014386T2 (de) * 1999-06-03 2005-10-13 Eli Lilly And Co., Indianapolis Verfahren zur herstellung von 10,11methanodibenzosuberanderivaten
WO2002005818A2 (en) * 2000-07-18 2002-01-24 Eli Lilly And Company Novel method of use of multidrug resistance modulators
DE60202944T2 (de) 2001-04-25 2006-03-23 Eli Lilly And Co., Indianapolis Neue salze und kristalline formen von (2r)-anti-5-3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy quinolin
US11930815B1 (en) 2023-08-29 2024-03-19 King Faisal University 3,3′-(piperazine-1,4-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) as insecticidal agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
JPS6147466A (ja) * 1984-08-10 1986-03-07 Dainippon Pharmaceut Co Ltd アミン誘導体
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives

Also Published As

Publication number Publication date
KR20020038587A (ko) 2002-05-23
US6521755B1 (en) 2003-02-18
IL146810A (en) 2007-06-03
CA2378735A1 (en) 2000-12-14
JP2003501421A (ja) 2003-01-14
BR0011559A (pt) 2002-02-26
WO2000075121A2 (en) 2000-12-14
CO5170530A1 (es) 2002-06-27
MY123517A (en) 2006-05-31
KR100692351B1 (ko) 2007-03-09
AU5123300A (en) 2000-12-28
EP1189887A2 (en) 2002-03-27
TWI267511B (en) 2006-12-01
AR037068A1 (es) 2004-10-20
HUP0203421A3 (en) 2003-05-28
HUP0203421A2 (hu) 2003-02-28
MXPA01012296A (es) 2002-07-30
IL146810A0 (en) 2002-07-25
WO2000075121A3 (en) 2001-04-26
SV2002000088A (es) 2002-01-23
EG24072A (en) 2008-05-11

Similar Documents

Publication Publication Date Title
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
PE20030612A1 (es) Benzoimidazoles
HK1081543A1 (en) Process for preparing 5-(1,3-oxazol-2-yl) benzoic acid derivatives
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
BRPI0411365A (pt) derivados de aminopiridina
ATE381542T1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
PE20030574A1 (es) N-[benzoil]heteroarilsulfonamida como agentes antineoplasicos
CY1111980T1 (el) Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
CY1107753T1 (el) 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
PE20010216A1 (es) Procedimiento para preparar derivados de 10,11-metanobenzosuberano
EA200200302A1 (ru) Полиморфная соль
TR200402546T4 (tr) Taksan türevleri hazırlamak için işlem.
EP1253139A3 (en) Multioligoanilinated fullerenes
DE69510510D1 (de) N-benzoylmethylsubstituierte paroxetinderivate
JP2007507467A5 (es)
DE60020573D1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
ATE293591T1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
GB0003257D0 (en) Heterocyclic compounds and their therapeutic use

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed